Comments

Regeneron Pharmaceuticals Stock Price, Quotes and Forecasts

Q: What sector and industry does Regeneron Pharmaceuticals (REGN) operate in?

Regeneron Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

REGNNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$604.62

-10.17-1.65%

At close: -

$604.75

0.130.02%

After Hours: 6:28 PM EDT

The dividend Ex-Date was 2 days ago

23andMe Holding Co announced it will sell assets to Regeneron Pharmaceuticals (REGN) on Monday, May 19, 2025 for $256.0M

Regeneron Pharmaceuticals (REGN) Forecast

News Earnings Regeneron Pharmaceuticals (REGN) Options Guidance Dividends Analyst Ratings Insider Trades Government Trades Short Interest

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Regeneron Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:REGN | Benzinga

Explore Regeneron Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for REGN.

Open	$613.05
Close	$604.62
Volume / Avg.	1.09M / 1.14M
Day Range	$597.92 - $617.52
52 Wk Range	520.50 - 1.21K
Market Cap	$65.29B
P/E Ratio	15.63
Dividend Yield	0.57%
Exchange	NASDAQ
RSI	54
Short Interest	2.82%
Days to Cover	2.41

Recent News

Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal

Regeneron (REGN) to acquire 23andMe for $256 million, plans to maintain consumer services and uphold privacy policies. Deal expected to close Q3 2025.

Akanksha Bakshi

3 Stocks That Will Profit From Trump's Drug Price Cut

Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest.

Nic Chahine

Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025

As of mid-May 2025, the S&P 500 has turned positive year-to-date (YTD) for the first time in many weeks. Stocks across multiple sectors have broadly recovered from the jolt of tariff news and other volatility

MarketBeat

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Feb

Mar

Apr

May

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.9

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$613.05
Close	$604.62
Volume / Avg.	1.09M / 1.14M
Day Range	$597.92 - $617.52
52 Wk Range	520.50 - 1.21K
Market Cap	$65.29B
P/E Ratio	15.63
Dividend Yield	0.57%
Exchange	NASDAQ
RSI	54
Short Interest	2.82%
Days to Cover	2.41

About Regeneron Pharmaceuticals, Inc.

Sector

Health Care

Industry

Biotechnology

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, c...

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

How do I buy Regeneron Pharmaceuticals (REGN) stock?

You can purchase shares of Regeneron Pharmaceuticals (NASDAQ:REGN) through any online brokerage.

View our list of the best stock brokerages

Who are Regeneron Pharmaceuticals (REGN) competitors?

Other companies in Regeneron Pharmaceuticals’s space includes: BeiGene (NASDAQ:ONC), Exact Sciences (NASDAQ:EXAS), Neurocrine Biosciences (NASDAQ:NBIX), Roivant Sciences (NASDAQ:ROIV) and Amgen (NASDAQ:AMGN).

What is the forecast, or price target, for Regeneron Pharmaceuticals (REGN) stock?

Regeneron Pharmaceuticals has a consensus price target of $923.42.

What is the current price for Regeneron Pharmaceuticals (REGN)?

The stock price for Regeneron Pharmaceuticals (NASDAQ: REGN) is $604.75 last updated May 21, 2025 at 6:28 PM EDT.

Does Regeneron Pharmaceuticals (REGN) pay a dividend?

A quarterly cash dividend of 0.88 per share of Class A Common Stock. The quarterly cash dividend was payable on June 6, 2025 to stockholders of record on May 20, 2025.

When is Regeneron Pharmaceuticals (NASDAQ:REGN) reporting earnings?

Regeneron Pharmaceuticals’s Q2 earnings are confirmed for Thursday, July 31, 2025.

Is Regeneron Pharmaceuticals (REGN) going to split?

There is no upcoming split for Regeneron Pharmaceuticals.

What sector and industry does Regeneron Pharmaceuticals (REGN) operate in?

Regeneron Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.